SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform to offer ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...

Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ...

SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform to offer long-term medical therapy for chronic ophthalmic conditions, including ...

Financing supports SpyGlass Pharma's platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic ...

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.